top of page
Scientist Using Microscope

Durin Technologies Inc. Welcomes You

Diagnostics for a Better Tomorrow

Home: Welcome

Vision

At Durin Technologies Inc., we believe that early disease detection is the key to increasing the prospects for successful treatment outcomes.  Our focus lies in developing diagnostic tests for the most prevalent and devastating neurodegenerative diseases that make possible both early detection and monitoring of disease progression.

Microscope
2020 Edison Patent Award Recipient
Dr. Robert G Nagele

Rowan University and inventor Dr. Robert G Nagele receives a patent award in the Medical Health Diagnostic category for “Diagnostic Biomarker Profiles for the Detection and Diagnosis of Alzheimer’s Disease” (U.S. 10,132,817). This invention provides methods, compositions and kits for a blood test for early diagnosis of Alzheimer’s disease (AD) based on detection of disease-specific autoantibodies as blood-based biomarkers. The goal is to definitively diagnose early-stage AD in patients that arrive for the first time in their doctor’s office with a cognitive or memory complaint. Currently, diagnosing early-stage AD has been difficult and often inconclusive even after using expensive neuropsychological evaluations and brain imaging. This test is based on the finding that all humans have thousands of self-reactive antibodies (called autoantibodies) in their blood that function to clear cell and tissue debris their bodies generate daily. Relevant to the patent, in the presence of disease, the amount of cell debris produced and released into the blood by the diseased organs or tissues is dramatically increased. In response, the immune system markedly increases production of the specific autoantibodies charged with clearing this disease-specific debris from the blood. This new test uses a single drop of blood to detect the increased levels of these disease-associated autoantibodies as blood-based biomarkers for early AD detection. Thus far, there are no blood-based diagnostic tests for early-stage AD. The development of an accurate, relatively noninvasive, inexpensive blood-based diagnostic test for early stages of AD will be of great benefit to patients afflicted with this disease since early treatment greatly increases the likelihood of a successful outcome. In addition, it would allow earlier enrollment into AD clinical trials seeking new treatments and would also facilitate the monitoring of disease progression in patients who are under treatment by their physicians or participating as subjects in clinical trials. Rowan University has licensed a portfolio of technologies in the neurodegenerative sector (including this patent) to a startup, Durin Technologies. Durin has managed to raise significant investment from different sources and is currently moving forward in seeking FDA approval for blood-based tests for preclinical (presymptomatic) AD, prodromal AD and mild-moderate AD using autoantibodies as biomarkers and human protein microarrays as a platform.

OUR PUBLICATIONS

Early Detection of Alzheimer’s Disease-Related Pathology Using a Multi-Disease Diagnostic Platform Employing Autoantibodies as Blood-based Biomarkers

2022, (Under Review)

Evidence that Brain-Reactive Autoantibodies Contribute to Chronic Neuronal Internalization of Exogenous Amyloid-β1-42 and Key Cell Surface Proteins During Alzheimer's Disease Pathogenesis

Journal of Alzheimer's Disease  March 10, 2020

See publication

 

The origin and nature of the complex autoantibody profile in cerebrospinal fluid

Brain, Behavior, & Immunity - Health  December 29, 2019

See publication

 

Detection of early-stage Alzheimer's pathology using blood-based autoantibody biomarkers in elderly hip fracture repair patients.

PLoS One  November 15, 2019

See publication

 

Autoantibodies as diagnostic biomarkers for the detection and subtyping of Multiple Sclerosis

Journal of Neuroimmunology  May 19, 2017

See publication

Detection of Alzheimer’s disease at Mild Cognitive Impairment and disease progression using autoantibodies as blood-based biomarkers

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring  April 12, 2016

See publication

Serum autoantibodies as biomarkers for Parkinson’s disease: background and utility

AIMS Medical Science  October 10, 2015

See publication

Sevoflurane and Isoflurane induce structural changes in brain vascular endothelial cells and increase blood-brain barrier permeability: Possible link to postoperative delirium and cognitive decline

Brain Research  September 16, 2015

See publication

Potential utility of autoantibodies as blood-based biomarkers for early detection and diagnosis of Parkinson's disease

Immunology Letters  September 16, 2015

See publication

Utility of autoantibodies as biomarkers for diagnosis and staging of neurodegenerative disease

International Review of Neurobiology  June 19, 2015

See publication

Natural IgG autoantibodies are abundant and ubiquitous in human sera, and their number is influenced by age, gender, and disease

PLoS One  April 2, 2013

See publication

Diabetes and hypercholesterolemia increase blood-brain barrier permeability and brain amyloid deposition: beneficial effects of the LpPLA2 inhibitor darapladib

Journal of Alzheimer's Disease  March 29, 2013

See publication

Neuronal PAD4 expression and protein citrullination: possible role in production of autoantibodies associated with neurodegenerative disease

Journal of Autoimmunity  May 2, 2012

See publication

Diagnosis of Parkinson's disease based on disease-specific autoantibody profiles in human sera

PLoS One  February 22, 2012

See publication

Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera

PLoS One  August 3, 2011

See publication

More Recent News

Creating a Buzz in Media Outlets Nationwide

NAGELE photo.jpg

South Jersey health care startup raises $3.5 million

A South Jersey life sciences company developing a blood test for the early detection of Alzheimer's and Parkinson's disease, when treatments are likely to be more effective, has raised $3.5 million in equity financing.

PXL_20220614_175707172_edited.jpg

Durin Technologies discusses future ventures and collaborations at BIO 2022

Durin Technologies attended BIO2022 at San Diego, CA in June earlier this year.

"BIO is the world’s largest advocacy association representing member companies...

icon.png

Durin Introduces DURITECT-AD at Neuroscience 2022

Scientists and industry professionals from around the world gather every year to discover new ideas, share their research and experience the latest in the field at the Neuroscience conference organized by SFN. This year it was held at the San Diego Convention Center between November 12-16...

bottom of page